IBSA Institut Biochimique SA
IBSA Institut Biochimique SA is a Originators company based in Lugano (Ticino) recorded by Swissmedic as the authorisation holder for 44 human medicines. That places it 33 of 334 authorisation holders in Switzerland. Its portfolio is concentrated in Synthetika.
Key facts
| Sector | Originators |
|---|---|
| City | Lugano |
| Canton | Ticino |
| Authorisation holder | Yes |
| Medicines | 44 |
| Founded | 1945 |
| Employees | 1001-5000 |
| Parent group | Not available |
| Activity | Not available |
| Website | ibsagroup.com |
Medicines authorised in Switzerland
IBSA Institut Biochimique SA is recorded by Swissmedic as the authorisation holder for 44 human medicines. The table shows 44 of them with product code and dispensing category.
Portfolio by product code
Portfolio by dispensing category
44 of 44 authorisations
| Name | Authorisation number | Dispensing category | ATC | First authorised |
|---|---|---|---|---|
| Betesil | 62621 | B | - | 2013-05-07 |
| Biovigor | 54155 | D | B03BA53 | 1997-04-18 |
| Choriomon 10'000 | 33524 | B | G03GA01 | 1968-01-15 |
| Condromed 200 mg / 250 mg | 68626 | B | - | 2023-01-11 |
| Condrosulf 400 | 42277 | B | M01AX25 | 1982-11-05 |
| Condrosulf 400 | 48557 | B | M01AX25 | 1986-12-29 |
| Condrosulf 800 | 51610 | B | M01AX25 | 1991-10-31 |
| Effigel | 55429 | D | M02AA15 | 2002-03-08 |
| Effigel | 62600 | D | - | 2014-02-19 |
| Flectoparin Tissugel | 57347 | D | M02AA15 | 2006-07-14 |
| Flector Dolo Liquid Caps 12.5 mg | 67855 | D | M01AB05 | 2021-08-04 |
| Flector EP | 50716 | D | - | 1991-03-28 |
| Flector EP 25 mg | 49065 | B | M01AB05 | 1995-12-13 |
| Flector EP Tissugel | 52022 | D | M02AA15 | 1993-06-25 |
| Flector Plus Tissugel | 65998 | D | M02AA15 | 2016-03-23 |
| Fostimon 75 U.I. | 52974 | A | G03GA04 | 1996-07-18 |
| Ialugen | 48118 | D | D03AX05 | 1988-11-29 |
| Ialugen | 48119 | D | D03AX05 | 1988-11-29 |
| Ialugen plus | 51722 | B/D | D06BA51 | 1992-12-23 |
| Ialugen plus | 51970 | B/D | D06BA51 | 1992-12-23 |
| Ialugen Plus Akut | 68027 | D | D06BA51 | 2021-09-02 |
| ialugen Plus Visc | 60185 | B | D06BA51 | 2010-07-26 |
| Lorazepam IBSA 1.0 mg | 70218 | B | N05BA06 | 2026-06-04 |
| Merional 75 U.I. | 52703 | A | G03GA02 | 1996-07-18 |
| Merional HG 75 I.U. | 61261 | A | G03GA02 | 2011-07-15 |
| Merional HG 900 I.E. Multidose | 68570 | A | G03GA02 | 2022-09-20 |
| Myrtaven | 49506 | B | C05CX | 1988-09-05 |
| Neurodol Tissugel | 54746 | B | D04AB01 | 1999-04-30 |
| Prolutex 25 mg | 63225 | A | G03DA04 | 2014-06-13 |
| Prolutex Ready 25 mg | 69079 | A | G03DA04 | 2023-11-14 |
| Silvir 25 mg | 65881 | B | G04BE03 | 2016-10-27 |
| Solmucalm | 53336 | D | R05CB10 | 1997-10-10 |
| Solmucalm tosse grassa | 57854 | D | R05CB10 | 2008-08-14 |
| Solmucol 100 | 47909 | B/D | R05CB01 | 1986-06-24 |
| Solmucol 20% antidoto | 66433 | B | V03AB23 | 2018-06-14 |
| Solmucol 600 | 58066 | D | R05CB01 | 2007-07-31 |
| Solmucol 600 tosse grassa | 57868 | D | R05CB01 | 2007-12-14 |
| Solmucol 600 tosse grassa | 58027 | D | R05CB01 | 2007-07-31 |
| Solmucol Bronchoprotect 50 mg | 67822 | D | R07AX | 2022-01-06 |
| Solmucol Raffreddore | 55332 | D | R01AA07 | 2000-12-21 |
| Solmucol tosse grassa 100 mg | 50046 | D | R05CB01 | 1989-03-17 |
| Solmucol tosse grassa 100 mg/5 ml | 52254 | D | R05CB01 | 1993-10-14 |
| Tirosint 25 μg | 57455 | B | H03AA01 | 2006-04-06 |
| Tirosint Solution 13 μg | 66695 | B | - | 2018-10-11 |
Frequently asked questions
How many medicines does IBSA Institut Biochimique SA have authorised in Switzerland?
IBSA Institut Biochimique SA is recorded by Swissmedic as the authorisation holder for 44 human medicines (as of 1 September 2026). Different strengths under one authorisation number are not counted separately.
Where is IBSA Institut Biochimique SA based?
The Swiss location recorded for IBSA Institut Biochimique SA is Lugano, Ticino.
Is IBSA Institut Biochimique SA a Swissmedic authorisation holder?
Yes. IBSA Institut Biochimique SA appears in the official Swissmedic list of authorised medicinal products as an authorisation holder. Under the Therapeutic Products Act (TPA) the holder is responsible for the quality, safety and product information of its medicines in Switzerland.